Long-Term Intramuscular Recombinant DNA Interferon α2Therapy in Subacute Sclerosing Panencephalitis: Reduction of Serum Measles Antibodies without Clinical Improvement
作者:
R. Crols,
A. Lowenthal,
期刊:
European Neurology
(Karger Available online 1987)
卷期:
Volume 27,
issue 2
页码: 72-77
ISSN:0014-3022
年代: 1987
DOI:10.1159/000116134
出版商: S. Karger AG
关键词: Interferon;Measles antibodies;Subacute sclerosing panencephalitis
数据来源: Karger
摘要:
Two patients with subacute sclerosing panencephalitis (SSPE) were treated intramuscularly with recombinant DNA interferon-a2 for 3 and 6 months, respectively. Side effects were minimal. No objective clinical response could be noted. In a patient with stable SSPE, a significant decrease in serum antimeasles antibody levels was observed. This decrease was less pronounced in another patient with evolutive SSPE. The results of this study were compared to findings published previously. The reasons for the lack of clinical efficacy of interferon in SSPE are discussed.
点击下载:
PDF
(787KB)
返 回